Tongji Hospital
同济大学附属同济医院
Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Tongji Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
- Stomach cancer胃癌17 papers led
- Osteosarcoma骨肉瘤2 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤2 papers led
- Multiple myeloma多发性骨髓瘤2 papers led1 open trial led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
- Aplastic anaemia再生障碍性贫血0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病0 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Correlation of 3'-phosphoadenosine-5'-phosphosulfate synthase 1 (PAPSS1) expression with clinical parameters and prognosis in esophageal squamous cell carcinoma.
- Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway.
- A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma.
More papers found outside PubMed (not counted)15
- Tislelizumab combined with radiotherapy for unresectable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II study (TREC)
- Letter to the Editor: Human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy
- Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- miR-139-5p mediates TGIF1 to regulate the TGFβ pathway and inhibit growth of esophageal squamous cell carcinoma cells
- Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Design and synthesis of copper nanoparticles for the treatment of human esophageal cancer: introducing a novel chemotherapeutic supplement
- Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
Cancer
Stomach cancer
胃癌Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06081647
Age 18 years to 60 years (registered criteria)
Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led17
- Diffusion-weighted MRI of advanced gastric cancer: correlations of the apparent diffusion coefficient with Borrmann classification, proliferation and aggressiveness.
- The m1A-SFRP2-NFAT/TOX axis governs T cell exhaustion in gastric cancer.
- Machine learning-based prediction of gastroesophageal junction cancer using electronic medical records.
- p53 inhibits OTUD5 transcription to promote GPX4 degradation and induce ferroptosis in gastric cancer.
- Tumor Immune Contexture Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer.
- Exploring Potential Hub Genes and Molecular Mechanisms Linking Cardia Carcinoma With Sjögren's Syndrome Based on Comprehensive Bioinformatics Analysis and Machine Learning.
- Indolent T-cell lymphoma of the gastrointestinal tract coexisting with gastric signet-ring cell carcinoma: A case report and review of literature.
- Identifying and validating angiogenesis-related genes remodeling tumor microenvironment and suppressing immunotherapy response in gastric cancer.
- Overexpression of Glycosyltransferase 8 Domain Containing 1 Promotes Gastric Cancer Proliferation and Inhibits Apoptosis via Mediating PTPN6/JAK2/STAT3 Signaling Axis.
- γ-tocotrienol regulates gastric cancer by targeting notch signaling pathway.
- Tranditional Roux-en-Y vs Uncut Roux-en-Y in Laparoscopic Distal Gastrectomy: a Randomized Controlled Study.
- Assessing clinical trial failure risk factors and reasons in gastric cancer.
- A comprehensive analysis of potential gastric cancer prognostic biomarker ITGBL1 associated with immune infiltration and epithelial-mesenchymal transition.
- Multidimensional study of cell division cycle-associated proteins with prognostic value in gastric carcinoma.
- Application of Endoscopic Ultrasound Combined with Multislice Spiral CT in Diagnosis and Treatment of Patients with Gastrointestinal Eminence Lesions.
- Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization.
- Expression and mechanism of exosome-mediated A FOXM1 related long noncoding RNA in gastric cancer.
All its trials on ClinicalTrials.gov, any status5
- The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in Obesity
- High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol
- WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
- Adverse Events During Upper Gastrointestinal Endoscopy
Cancer
Osteosarcoma
骨肉瘤Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)4
- Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway.
- Long Noncoding RNA SNHG16 Promotes Osteosarcoma Cells Migration and Invasion via Sponging miRNA-340.
- Evaluating and Predicting the Probability of Death in Patients with Non-Metastatic Osteosarcoma: A Population-Based Study.
- Long non-coding RNA CCAT1/miR-148a axis promotes osteosarcoma proliferation and migration through regulating PIK3IP1.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.
16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingUniversal CAR-T Cell Therapy for MM
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT07248176
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingOriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06182696
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status10
- Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM
- Universal CAR-T Cell Therapy for MM
- Efficacy and Safety Evaluation of BCMA-UCART
- OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07043218
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Blood disorders
Aplastic anaemia
再生障碍性贫血Led no English-language PubMed papers on aplastic anaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shanghai for aplastic anaemia63 hospitals in China for aplastic anaemia
No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)3
- GPRC5A reduction contributes to pollutant benzo[a]pyrene injury via aggravating murine fibrosis, leading to poor prognosis of IIP patients.
- Response to: Comment on "Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis".
- Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis.
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other linked evidence
Getting in touch
Name card to show staff or a driver
同济大学附属同济医院
Tongji Hospital
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Tongji Hospital; Shanghai Tongji Hospital; Tongji Hospital of Tongji University; Tongji Hospital Affiliated to Tongji University; Shanghai Tongji Hospital Affiliated with Tongji University; Tongji Hospital Medical College of Tongji University; Shanghai Tongji Hospital Affiliated to Tongji University; Tongji Hospital Affiliated to Shanghai